Top

Published in:

01-09-2006 | General Reviews

Statins and Peripheral Arterial Disease: Potential Mechanisms and Clinical Benefits

Authors: Mohamad E. Alnaeb, MD, MRCS, Nasser Alobaid, MSc, MRCS, Alexander M. Seifalian, PhD, Dimitri P. Mikhailidis, MD, FRCPath, FRCP, George Hamilton, MD, FRCS

Published in: Annals of Vascular Surgery | Issue 5/2006

Abstract

Peripheral arterial disease (PAD) is a manifestation of widespread atherosclerosis. Lipid modification (especially with statins) is a component of the treatment of patients with PAD since this condition is considered a coronary heart disease equivalent. This review considers the mechanism of action of statins in PAD. Statins have been shown to reduce the incidence of new coronary events in patients with PAD. However, surveys suggest that many such patients remain undertreated. Statins can also increase walking distance in patients with PAD. There is also evidence that statins can improve renal function in these patients. Several other actions of statins are considered in this review. PAD patients have an increased morbidity and mortality, largely due to myocardial infarction and stroke. Recognizing and treating these high-risk patients as early as possible should be a priority.

Munger MA, Hawkins DW. Atherothrombosis: epidemiology, pathophysiology, and prevention. J Am Pharm Assoc (Wash) 2004;44:S5-S12

Gonzalez ER, Kannewurf BS. Atherosclerosis: a unifying disorder with diverse manifestations. Am J Health Syst Pharm 1998;55:S4-S7PubMed

Bettmann MA, Dake MD, Hopkins LN et al. Atherosclerotic Vascular Disease Conference: Writing Group VI: revascularization. Circulation 2004;109:2643-2650PubMed

Criqui MH, et al. The prevalence of peripheral arterial disease in a defined population. Circulation 1985;71:510-515PubMed

Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation 1995;91:1472-1479PubMed

CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339

Newman AB, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol 1999;19:538-545PubMed

Aronow WS, Ahn C. Frequency of new coronary events in older persons with peripheral arterial disease and serum low-density lipoprotein cholesterol ≥125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol 2002;90:789-791PubMed

McDermott MM, et al. Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease. Arch Intern Med 2003;163:2157-2162PubMed

10.

McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 1991;87:119-128PubMed

11.

Vogt MT, McKenna M, Anderson SJ, Wolfson SK, Kuller LH. The relationship between ankle-arm index and mortality in older men and women. J Am Geriatr Soc 1993;41:523-530PubMed

12.

Graham IM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775-1781PubMed

13.

Dieter RS, Chu WW, Pacanowski JP Jr, McBride PE, Tanke TE. The significance of lower extremity peripheral arterial disease. Clin Cardiol 2002;25:3-10PubMed

14.

Mukherjee D, et al. Missed opportunities to treat atherosclerosis in patients undergoing peripheral vascular interventions: insights from the University of Michigan Peripheral Vascular Disease Quality Improvement Initiative (PVD-QI2). Circulation 2002;106:1909-1912PubMed

15.

Aronow WS. Management of peripheral arterial disease. Cardiol Rev 2005;13:61-68PubMed

16.

Burns P, Gough S, Bradbury AW, et al. Management of peripheral arterial disease in primary care. BMJ 2003;326:584-588PubMed

17.

Antiplatelet therapy in peripheral arterial disease. Consensus statement. Eur J Vasc Endovasc Surg 2003;26:1-16

18.

Kroger K. Dyslipoproteinemia and peripheral arterial occlusive disease. Angiology 2004;55:135-138PubMed

19.

Mohler ER III, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003;108:1481-1486PubMed

20.

Anand SS, Kundi A, Eikelboom J, Yusuf S. Low rates of preventive practices in patients with peripheral vascular disease. Can J Cardiol 1999;15:1259-1263PubMed

21.

Clark AL, Byrne JC, Nasser A, McGroarty E, Kennedy JA. Cholesterol in peripheral vascular disease—a suitable case for treatment? QJM 1999;92:219-222PubMed

22.

McDermott MM, Mehta S, Ahn H, Greenland P. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med 1997;12:209-215PubMedCrossRef

23.

Harrison EM, Holdsworth RJ. How many claudicants should be prescribed statins? Eur J Vasc Endovasc Surg 2003;25:367-368PubMed

24.

Cimminiello C. PAD. Epidemiology and pathophysiology. Thromb Res 2002;106:V295-V301PubMed

25.

Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-874PubMed

26.

Mlot C. Chlamydia linked to atherosclerosis. Science 1996;272:1422PubMed

27.

Libby P. Changing concepts of atherogenesis. J Intern Med 2000;247:349-358PubMed

28.

Watson AD, et al. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem 1997;272:13597-13607PubMed

29.

Lefer AM, Ma XL. Decreased basal nitric oxide release in hypercholesterolemia increases neutrophil adherence to rabbit coronary artery endothelium. Arterioscler Thromb 1993;13:771-776PubMed

30.

Galis ZS, Sukhova GK, Kranzhofer R, Clark S, Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA 1995;92:402-406PubMed

31.

Davies MJ. Pathology of arterial thrombosis. Br Med Bull 1994;50:789-802PubMed

32.

Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-2850PubMed

33.

Silva JA, White CJ. Plaque instability in peripheral vessels. Prog Cardiovasc Dis 2002;44:429-436PubMed

34.

Pedersen TR, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Atherosclerosis 2004;5(Suppl.):81-87PubMed

35.

The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357

36.

Wheeler DC. Statins and the kidney. Curr Opin Nephrol Hypertens 1998;7:579-584PubMed

37.

Davis M, et al. The effect of short-term lipid lowering with atorvastatin on carotid artery intima media thickness in patients with peripheral vascular disease: a pilot study. Curr Med Res Opin 2000;16:198-204PubMed

38.

Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003;19:540-556PubMed

39.

Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97:1440-1445

40.

Sacks FM, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-1009PubMed

41.

Bellosta S, et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998;137(Suppl.):S101-S109PubMed

42.

Landmesser U, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005;111:2356-2363PubMed

43.

Anderson TJ, et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-493PubMed

44.

Treasure CB, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-487PubMed

45.

Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995;346:467-471PubMed

46.

John S, et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation 1998;98:211-216PubMed

47.

Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999;138:S419-S420PubMed

48.

Radomski MW, Moncada S. Regulation of vascular homeostasis by nitric oxide. Thromb Haemost 1993;70:36-41PubMed

49.

Matsagas MI, Geroulakos G, Mikhailidis DP. The role of platelets in peripheral arterial disease: therapeutic implications. Ann Vasc Surg 2002;16:246-258PubMed

50.

Cornwell TL, Arnold E, Boerth NJ, Lincoln TM. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am J Physiol 1994;267:C1405-C1413PubMed

51.

De Caterina R, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995;96:60-68PubMed

52.

Laufs U, La FV, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-1135PubMed

53.

Haaber AB, Eidemak I, Jensen T, Feldt-Rasmussen B, Strandgaard S. Vascular endothelial cell function and cardiovascular risk factors in patients with chronic renal failure. J Am Soc Nephrol 1995;5:1581-1584PubMed

54.

Hand MF, Haynes WG, Johnstone HA, Anderton JL, Webb DJ. Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney Int 1995;48:806-813PubMed

55.

Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-2016PubMed

56.

Daskalopoulou SS, Daskalopoulos ME, Liapis CD, Mikhailidis DP. Peripheral arterial disease: a missed opportunity to administer statins so as to reduce cardiac morbidity and mortality. Curr Med Chem 2005;12:443-452PubMed

57.

Elisaf M, Mikhailidis DP. Statins and renal function. Angiology 2002;53:493-502PubMed

58.

Athyros VG, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study. J Clin Pathol 2004;57:728-734PubMed

59.

Athyros VG, et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study. Am J Kidney Dis 2004;43:589-599PubMed

60.

Youssef F, et al. The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT). Eur J Vasc Endovasc Surg 2002;23:358-364PubMed

61.

Ludmer PL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-1051PubMedCrossRef

62.

Andrews TC, et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997;95:324-328PubMed

63.

Vita JA, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990;81:491-497PubMed

64.

Keidar S, Aviram M, Maor I, Oiknine J, Brook JG. Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: in vitro and in vivo studies. Br J Clin. Pharmacol. 1994;38:513-519PubMed

65.

Hussein O, Schlezinger S, Rosenblat M, Keidar S, Aviram M. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis 1997;128:11-18PubMed

66.

Milionis HJ, Elisaf MS, Mikhailidis DP. The effects of lipid-regulating therapy on haemostatic parameters. Curr Pharm Des 2003;9:2425-2443PubMed

67.

Tsuda Y, et al. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis 1996;122:225-233PubMed

68.

Lacoste L, et al. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995;92:3172-3177PubMed

69.

Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-213PubMed

70.

Lee AJ, Fowkes FG, Lowe GD, Rumley A. Fibrin D-dimer, haemostatic factors and peripheral arterial disease. Thromb Haemost 1995;74:828-832PubMed

71.

McDermott MM, et al. Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index. Am J Cardiol 2003;92:194-199PubMed

72.

Bustos C, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998;32:2057-2064PubMed

73.

Dimmeler S, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001;108:391-397PubMed

74.

Llevadot J, et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 2001;108:399-405PubMed

75.

Rupp S, et al. Statin therapy in patients with coronary artery disease improves the impaired endothelial progenitor cell differentiation into cardiomyogenic cells. Basic Res Cardiol 2004;99:61-68PubMed

76.

Kureishi Y, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000;6:1004-1010PubMed

77.

Alobaid N, et al. Endothelial progenitor cells and their potential clinical applications in peripheral arterial disease. Endothelium 2005;12:243-250PubMed

78.

Thor M, Yu A, Swedenborg J. Markers of inflammation and hypercoagulability in diabetic and nondiabetic patients with lower extremity ischemia. Thromb Res 2002;105:379-383PubMed

79.

Banerjee AK, et al. A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants. Thromb Haemost 1992;68:261-263PubMed

80.

Lassila R, et al. Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. Arterioscler Thromb 1993;13:1738-1742PubMed

81.

Cheshire NJ, Wolfe JH, Barradas MA, Chambler AW, Mikhailidis DP. Smoking and plasma fibrinogen, lipoprotein (a) and serotonin are markers for postoperative infrainguinal graft stenosis. Eur J Vasc Endovasc Surg 1996;11:479-486PubMed

82.

Goudevenos JA, et al. The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia–a pilot study involving serial sampling. Curr Med Res Opin 2001;16:269-275PubMed

83.

Koh KK, et al. Vascular effects of diet and statin in hypercholesterolemic patients. Int J Cardiol 2004;95:185-191PubMed

84.

Leng GC, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 1996;25:1172-1181PubMed

85.

Muluk SC, et al. Outcome events in patients with claudication: a 15-year study in 2777 patients. J Vasc Surg 2001;33:251-257PubMed

86.

Jelnes R, et al. Fate in intermittent claudication: outcome and risk factors. BMJ 1986;293:1137-1140PubMed

87.

Criqui MH, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-386PubMedCrossRef

88.

Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497

89.

Smith SC Jr, et al. AHA/ACC scientific statement. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001;104:1577-1579PubMed

90.

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023

91.

The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-2446

92.

Clarke R, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-1155PubMedCrossRef

93.

Criqui MH, Denenberg JO, Langer RD, Fronek A. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med 1997;2:221-226PubMed

94.

Marin R, et al. Cardiovascular risk factors in peripheral arterial disease. A study of 403 cases [in Spanish]. Rev Clin Esp 1993;193:357-362PubMed

95.

Novo S, et al. Prevalence of risk factors in patients with peripheral arterial disease. A clinical and epidemiological evaluation. Int Angiol 1992;11:218-229PubMed

96.

Zimmerman BR, et al. A prospective study of peripheral occlusive arterial disease in diabetes. III. Initial lipid and lipoprotein findings. Mayo Clin Proc 1981;56:233-242PubMed

97.

Smith I, Franks PJ, Greenhalgh RM, Poulter NR, Powell JT. The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of critical ischaemia. Eur J Vasc Endovasc Surg 1996;11:402-408PubMed

98.

Cheng SW, Ting AC, Wong J. Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease. Eur J Vasc Endovasc Surg 1997;14:17-23PubMed

99.

Price JF, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Lipoprotein (a) and development of intermittent claudication and major cardiovascular events in men and women: the Edinburgh Artery Study. Atherosclerosis 2001;157:241-249PubMed

100.

Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-2485PubMed

101.

Laufs U, La F, V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-1135

102.

Khan F, Litchfield SJ, Belch JJ. Cutaneous microvascular responses are improved after cholesterol-lowering in patients with peripheral vascular disease and hypercholesterolaemia. Adv Exp Med Biol 1997;428:49-54PubMed

103.

Kirk G, McLaren M, Muir AH, Stonebridge PA, Belch JJ. Decrease in P-selectin levels in patients with hypercholesterolaemia and peripheral arterial occlusive disease after lipid-lowering treatment. Vasc Med 1999;4:23-26PubMed

104.

Leng GC, Price JF, Jepson RG. Lipid-lowering for lower limb atherosclerosis. Cochrane Database Syst Rev 2000;CD000123

105.

Blankenhorn DH, et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation 1991;83:438-447PubMed

106.

Lewis B. Randomised controlled trial of the treatment of hyperlipidaemia on progression of atherosclerosis. Acta Med Scand Suppl 1985;701:53-57PubMed

107.

Pedersen TR, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 1998;81:333-335PubMed

108.

Kroon AA, van Asten WN, Stalenhoef AF. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med 1996;125:945-954PubMed

109.

Aronow WS, Nayak D, Woodworth S, Ahn C. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol. 2003;92:711-712PubMed

110.

McDermott MM, et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 2003;107:757-761PubMed

111.

Sarnak MJ, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-2169PubMed

112.

Moorhead JF. Lipids and the pathogenesis of kidney disease. Am J Kidney Dis 1991;17:65-70PubMed

113.

Alnaeb ME, Youssef F, Mikhailidis DP, Hamilton G. Short-term lipid-lowering treatment with atorvastatin improves renal function but not renal blood flow indices in patients with peripheral arterial disease. Angiology 2006;57:65-71PubMed

114.

Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003;14:1605-1613PubMed

115.

Wilson SH, et al. Lipid-lowering-independent effects of simvastatin on the kidney in experimental hypercholesterolaemia. Nephrol Dial Transplant 2003;18:703-709PubMed

116.

Massy ZA, Ma JZ, Louis TA, Kasiske BL. Lipid-lowering therapy in patients with renal disease. Kidney Int 1995;48:188-198PubMed

117.

Valdivielso P, et al. Atorvastatin in dyslipidaemia of the nephrotic syndrome. Nephrology (Carlton) 2003;8:61-64

118.

Youssef F, et al. The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology 2004;55:53-62PubMedCrossRef

119.

Daskalopoulou SS, Athyros VG, Elisaf M, Mikhailidis DP. Uric acid levels and vascular disease. Curr Med Res Opin 2004;20:951-954PubMed

120.

Hoieggen A, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;65:1041-1049PubMed

121.

Wheeler DC, Bernard DB. Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. Am J Kidney Dis 1994;23:331-346PubMed

122.

Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87:1781-1791PubMed

123.

Vieira JM Jr, Mantovani E, Tavares RL, et al. Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction. Nephrol Dial Transplant 2005;20:1582–1591PubMed

124.

Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996;348:1079-1082PubMed

125.

Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med 2001;344:431-442PubMed

126.

Conlon PJ, et al. Survival in renal vascular disease. J Am Soc Nephrol 1998;9:252-256PubMed

127.

Minuz P, et al. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation 2002;106:2800-2805PubMed

128.

Lerman LO, et al. Increased oxidative stress in experimental renovascular hypertension. Hypertension 2001;37:541-546PubMed

129.

Suresh M, Laboi P, Mamtora H, Kalra PA. Relationship of renal dysfunction to proximal arterial disease severity in atherosclerotic renovascular disease. Nephrol Dial Transplant 2000;15:631-636PubMed

130.

Wright JR, et al. Clinicopathological correlation in biopsy-proven atherosclerotic nephropathy: implications for renal functional outcome in atherosclerotic renovascular disease. Nephrol Dial Transplant 2001;16:765-770PubMed

131.

Kasiske BL. Relationship between vascular disease and age-associated changes in the human kidney. Kidney Int 1987;31:1153-1159PubMed

132.

Manttari M, Tiula E, Alikoski T, Manninen V. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 1995;26:670-675PubMed

133.

Khong TK, Missouris CG, Belli AM, MacGregor GA. Regression of atherosclerotic renal artery stenosis with aggressive lipid lowering therapy. J Hum Hypertens 2001;15:431-433PubMed

134.

Jardine AG, et al. fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study. Am J Transplant 2004;4:988-995PubMed

135.

Dahlof B, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906PubMed

136.

Sever PS, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-1158PubMed

137.

Athyros VG, et al. Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE study. Platelets 2005;16:65-71PubMed

138.

Athyros VG, et al. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens 2004;18:781-788PubMed

139.

LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340-2346PubMed

140.

Coresh J, Kwiterovich PO Jr. Small, dense low-density lipoprotein particles and coronary heart disease risk: a clear association with uncertain implications. JAMA 1996;276:914-915PubMed

141.

Aronow WS. Should hypercholesterolemia in older persons be treated to reduce cardiovascular events? J Gerontol A Biol Sci Med Sci 2002;57:M411-M413PubMed

142.

Aronow WS, Ahn C. Incidence of new coronary events in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol 2002;89:67-69PubMed

143.

Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990;301:309-314PubMedCrossRef

144.

Marschner IC, et al. Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) study. LIPID study investigators. J Am Coll Cardiol 2001;38:56-63PubMed

145.

LIPID Group Study. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002;359:1379-1387

146.

Schillinger M, et al. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J 2004;25:742-748PubMed

147.

Yokoi H, Nobuyoshi M, Mitsudo K, Kawaguchi A, Yamamoto A. Three-year follow-up results of angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) study. Circ J 2005;69:875-883PubMed

148.

Vigen C, Hodis HN, Selzer RH, Mahrer PR, Mack WJ. Relation of progression of coronary artery atherosclerosis to risk of cardiovascular events (from the Monitored Atherosclerosis Regression Study). Am J Cardiol 2005;95:1277-1282PubMed

149.

Balk EM, et al. Effects of statins on vascular structure and function: a systematic review. Am J Med 2004;117:775-790PubMed

150.

Meijer WT, et al. Peripheral arterial disease in the elderly: the Rotterdam Study. Arterioscler Thromb Vasc Biol 1998;18:185-192PubMed

151.

Fowkes FG. The measurement of atherosclerotic peripheral arterial disease in epidemiological surveys. Int J Epidemiol 1988;17:248-254PubMed

152.

Newman AB, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation 1993;88:837-845

153.

TransAtlantic Inter-Society Consensus (TASC). Management of peripheral arterial disease (PAD). Section D. Chronic critical limb ischaemia. Eur J Vasc Endovasc Surg 2000;19(Suppl. A):S144-S243

154.

Deedwania P, Volkova N. Dyslipidemia and lipid-lowering therapy in the elderly. Expert Rev Cardiovasc Ther 2005;3:453-463PubMed

155.

Aronow WS. Hypercholesterolemia. The evidence supports use of statins. Geriatrics 2003;58:18-31PubMed

Title: Statins and Peripheral Arterial Disease: Potential Mechanisms and Clinical Benefits
Authors: Mohamad E. Alnaeb, MD, MRCS
Nasser Alobaid, MSc, MRCS
Alexander M. Seifalian, PhD
Dimitri P. Mikhailidis, MD, FRCPath, FRCP
George Hamilton, MD, FRCS
Publication date: 01-09-2006
Publisher: Springer-Verlag
Published in: Annals of Vascular Surgery / Issue 5/2006
Print ISSN: 0890-5096
Electronic ISSN: 1615-5947
DOI: https://doi.org/10.1007/s10016-006-9104-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Statins and Peripheral Arterial Disease: Potential Mechanisms and Clinical Benefits

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2006

Carotid Endarterectomy with Bovine Pericardium Patch Angioplasty: Mid-Term Results

Dacron Patch Infection after Carotid Endarterectomy: Case Report and Review of the Literature

Subintimal Angioplasty of Supra- and Infrageniculate Arteries

Chronic Renal Insufficiency and Risk of Early Mortality in Patients Undergoing Carotid Endarterectomy

Intraoperative Peripherally Inserted Central Venous Catheter Central Venous Pressure Monitoring in Abdominal Aortic Aneurysm Reconstruction

Cardiac Medical Therapy among Patients Undergoing Abdominal Aortic Aneurysm Repair